Xenical Adolescent Safety, Efficacy Needs Further Study – JAMA Editorial
This article was originally published in The Tan Sheet
Executive Summary
More research is needed on Xenical (orlistat) therapy for adolescent weight loss, according to an editorial in the June 15 Journal of the American Medical Association
You may also be interested in...
Xenical Pediatric AERs Need Continued Monitoring, FDA Says
Pediatric adverse events associated with Roche's Xenical (orlistat) could be a concern for FDA when an attempt is made to switch the drug over the counter
Xenical Rx-To-OTC Switch Filing Slated For 2005
GlaxoSmithKline will file for an Rx-to-OTC switch of Xenical (orlistat) a year earlier than expected
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC